Clinical trial tests a PARP inhibitor in urothelial cancer with DNA-repair defects
Urothelial carcinoma (UC), or bladder cancer, is the most common cancer of the urinary tract with limited treatment options. A new clinical trial aims to see how this type of cancer reacts to olaparib, a drug designed to target cancers that have defective DNA-repair mechanisms in their cells by inhibiting the action of PARP, an enzyme that can repair breaks in DNA. Read more...
African Postdoctoral Training Initiative fellow looks forward to collaborating within NCI
Apr 18, 2019
Rania Labib, Ph.D., is a postdoctoral fellow in the NIH African Postdoctoral Training Initiative (APTI) working in the lab of Beverly Mock, Ph.D., Deputy Chief of the Laboratory of Cancer Biology and Genetics. As part of the fellowship, she will spend two years at NCI conducting initial experiments in Dr. Mock’s lab, where she hopes to make a difference in possible treatment options for children with Burkitt’s lymphoma. Read more...
Envelope glycoprotein mutations allow HIV-1 to escape antiretroviral therapy in a lab-based study
Apr 12, 2019
CCR investigators have discovered that HIV-1 can compensate for a variety of mutations that block its replication by acquiring mutations in the envelope glycoprotein. Because antiretroviral therapies work by inhibiting viral replication, these findings may have implications for HIV-1 drug resistance. Read more...
MEK inhibitor selumetinib granted breakthrough designation by FDA to treat neurofibromatosis type 1 in pediatric patients
Apr 12, 2019
The U.S. Food and Drug Administration last week granted breakthrough therapy designation for the MEK 1/2 inhibitor selumetinib. The designation is for the treatment of pediatric patients aged three years and older with neurofibromatosis type 1 (NF1) symptomatic and/or progressive, inoperable plexiform neurofibromas (PN), a rare, incurable genetic condition. Read more...
Elaine Jaffe receives the 2019 USCAP Board’s Distinguished Pathologist award
Apr 11, 2019
Elaine Jaffe, M.D., Senior Investigator in the Laboratory of Pathology, has received the 2019 United States and Canadian Academy of Pathology (USCAP) Board’s Distinguished Pathologist award. The award recognizes an individual for making major contributions to pathology over the years. Read more...
New study delivers chemotherapy to the liver for metastatic colorectal cancer patients
Apr 3, 2019
In some patients, colorectal cancer spreads only to the liver. Patients with previously treated colorectal cancer that has spread only to the liver may be eligible to participate in a new clinical trial at the NIH Clinical Center. Read more...
CCR staff receive funding from the Department of Defense
Apr 2, 2019
Congratulations to the CCR staff who have received funding from the Department of Defense (DoD) Congressionally Directed Medical Research Program (CDMRP). The CDMRP office manages medical research programs in breast, prostate and ovarian cancers, neurofibromatosis, military health and other specified areas. Read more...
Stephanie Goff featured in an episode of The Doctors
Apr 1, 2019
Stephanie Goff, M.D., Associate Research Physician in CCR’s Surgery Branch, was recently featured on The Doctors. In the clip, she discusses how harnessing the body’s own immune system and adoptive cell transfer (ACT) can treat certain types of cancer. Read more...
New clinical trial will determine if gliomas respond to immunotherapy
Apr 1, 2019
Gliomas make up about 80 percent of all malignant brain tumors. A new clinical trial at the Center for Cancer Research is investigating if the immunotherapy drug nivolumab is beneficial to patients with gliomas. Read more...
Harnessing T-cell “stemness” could enhance cancer immunotherapy
Mar 28, 2019
A new study led by Nicholas Restifo, M.D., Senior Investigator in CCR’s Surgery Branch, sheds light on one way tumors may continue to grow despite the presence of cancer-killing immune cells. The findings, published March 29, 2019, in Science, suggest a way to enhance the effectiveness of immunotherapies for cancer treatment. Read more...
Trial results show that younger lymphoma patients respond well to ibrutinib
Mar 26, 2019
A recent clinical trial using the drug ibrutinib reveals that patients under age 60 with diffuse large B-cell lymphoma are much more likely to tolerate the drug – and respond to it – compared to those age 60 and older. Read more...